Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1

Status

Completed 5

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1

Conditions

Neoplasms 8Recurrence 5Neoplasm Metastasis 5Lymphoma 5Breast Neoplasms 5Sarcoma 4Endometrial Neoplasms 4Prostatic Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Glioblastoma 2Solid Tumors 1Solid Tumor 1Primary Myelofibrosis 1Osteosarcoma 1Myelodysplastic Syndromes 1Liposarcoma 1Leukemia 1Leiomyosarcoma 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Central Nervous System Neoplasms 1Bone Neoplasms 1

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Recurrence × ridaforolimus × Clear all
NCT01380184 2019-04-19

MK-8669-059

Merck Sharp & Dohme LLC

Phase 1 Completed
15 enrolled 15 charts

Neoplasms, Recurrence

NCT01256268 2017-08-30

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
24 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms, Recurrence, Endometrial Neoplasms

NCT00086125 2015-08-19

Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 2 Completed
57 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Recurrence, Hematologic Neoplasms, Primary Myelofibrosis

NCT01071304 2015-04-10

Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)

Merck Sharp & Dohme LLC

Phase 1 Completed
16 enrolled

Neoplasm Metastasis, Recurrence

NCT00112372 2015-02-12

Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 1 Completed
147 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡